Infinium Pharmachem (INFINIUM) Stock Overview
Engages in the manufacture and supply of iodine, iodine derivatives, and active pharmaceutical ingredients (APIs) in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
INFINIUM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Infinium Pharmachem Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹239.80 |
| 52 Week High | ₹337.00 |
| 52 Week Low | ₹213.90 |
| Beta | 0.28 |
| 1 Month Change | -9.17% |
| 3 Month Change | -4.08% |
| 1 Year Change | -23.90% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 224.49% |
Recent News & Updates
Recent updates
Shaky Earnings May Not Tell The Whole Story For Infinium Pharmachem (NSE:INFINIUM)
Nov 21
Is Infinium Pharmachem (NSE:INFINIUM) Using Too Much Debt?
Feb 12Investors Still Aren't Entirely Convinced By Infinium Pharmachem Limited's (NSE:INFINIUM) Earnings Despite 38% Price Jump
Sep 20Many Still Looking Away From Infinium Pharmachem Limited (NSE:INFINIUM)
Aug 04Infinium Pharmachem (NSE:INFINIUM) Strong Profits May Be Masking Some Underlying Issues
Jun 12Infinium Pharmachem (NSE:INFINIUM) Strong Profits May Be Masking Some Underlying Issues
Nov 06Shareholder Returns
| INFINIUM | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -3.9% | -0.7% | -0.8% |
| 1Y | -23.9% | -2.8% | -2.0% |
Return vs Industry: INFINIUM underperformed the Indian Pharmaceuticals industry which returned -3.3% over the past year.
Return vs Market: INFINIUM underperformed the Indian Market which returned -2% over the past year.
Price Volatility
| INFINIUM volatility | |
|---|---|
| INFINIUM Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in IN Market | 8.5% |
| 10% least volatile stocks in IN Market | 3.0% |
Stable Share Price: INFINIUM has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: INFINIUM's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 144 | Sanjaykumar Patel | infiniumpharmachem.com |
Infinium Pharmachem Limited engages in the manufacture and supply of iodine, iodine derivatives, and active pharmaceutical ingredients (APIs) in India and internationally. The company provides iodine based molecules/APIs/iodination reaction based bulk drugs. It also offers potassium iodide and iodate, sodium iodide, iodine, povidone iodine, pralidoxime iodide, thymol iodide, and iodoform products.
Infinium Pharmachem Limited Fundamentals Summary
| INFINIUM fundamental statistics | |
|---|---|
| Market cap | ₹3.74b |
| Earnings (TTM) | ₹93.40m |
| Revenue (TTM) | ₹1.57b |
Is INFINIUM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INFINIUM income statement (TTM) | |
|---|---|
| Revenue | ₹1.57b |
| Cost of Revenue | ₹1.16b |
| Gross Profit | ₹404.22m |
| Other Expenses | ₹310.82m |
| Earnings | ₹93.40m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.99 |
| Gross Margin | 25.78% |
| Net Profit Margin | 5.96% |
| Debt/Equity Ratio | 14.6% |
How did INFINIUM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/05 15:25 |
| End of Day Share Price | 2025/12/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Infinium Pharmachem Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.